8-K: DarioHealth Secures $32.5 Million Credit Facility with Potential for Additional $17.5 Million

DarioHealth Corp. has entered into a credit agreement for $32.5 million with the possibility of borrowing an additional $17.5 million, aimed at satisfying prior debt and supporting general business operations.

Summary

• DarioHealth Corp. has secured a $32.5 million credit facility with Callodine Commercial Finance, LLC, as agent, and other financial institutions as lenders.
• The company has the option to draw an additional $17.5 million, with $2.5 million contingent on achieving certain revenue and gross margin thresholds.
• The remaining $15.0 million is subject to the discretion of the agent and lenders.
• The credit agreement spans five years, maturing in April 2030.
• The loan is guaranteed by DarioHealth's subsidiaries and secured by substantially all of the company's and its subsidiaries' assets.
• The interest rate is based on the Term SOFR Rate plus 7.75% per annum.
• Upon maturity or an event of default, the interest rate will increase to the lesser of 3% over the contract rate or the maximum rate permitted by applicable laws.
• DarioHealth will issue warrants to purchase 2,114,140 shares of its common stock at an exercise price of $0.8278, with a seven-year term, for the lenders or their affiliates.
• Up to $2.5 million of the term loan can be converted into shares of DarioHealth's common stock at $0.9933 per share.
• The credit agreement's execution and the term loan's funding satisfied and terminated the prior Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company. However, the debt and associated covenants introduce risks, leading to a moderate sentiment score.

Positives

• The new credit facility provides DarioHealth with significant capital to satisfy prior debt and support its business operations.
• The option to draw an additional $17.5 million provides flexibility for future growth and strategic initiatives.
• The termination of the previous loan agreement simplifies the company's capital structure.

Negatives

• The loan is secured by substantially all of the company's and its subsidiaries' assets, increasing the risk in case of default.
• The credit agreement contains covenants that may restrict the company's ability to take certain actions, such as incurring additional debt or paying dividends.
• Voluntary prepayments of the term loan prior to the third anniversary of the closing are subject to pre-payment penalties.

Risks

• Failure to meet revenue and gross margin thresholds could limit access to the additional $2.5 million term loan.
• The lenders have discretion over whether to provide the additional $15.0 million term loan.
• The company's ability to operate is restricted by covenants in the credit agreement.
• The company is subject to customary events of default, including nonpayment, breach of covenants, and insolvency events.

Future Outlook

The credit facility is intended to provide DarioHealth with the financial resources to support its ongoing operations and strategic initiatives. The company's ability to access the additional $17.5 million will depend on its financial performance and the lenders' discretion.

Industry Context

In the digital health space, securing debt financing can provide companies with the capital needed to scale their operations, invest in product development, and expand their market reach. This credit facility positions DarioHealth to continue its growth trajectory in a competitive market.

Comparison to Industry Standards

• Comparable companies in the digital health space, such as Teladoc Health and Livongo (prior to its acquisition by Teladoc), have utilized a mix of equity and debt financing to fund their growth.
• The interest rate and terms of the credit facility appear to be within the typical range for venture debt in the current market environment.
• The inclusion of warrants is a common feature in venture debt deals, providing the lenders with potential upside in the company's equity.

Stakeholder Impact

• Shareholders: The credit facility provides financial stability and potential for growth, but also introduces risks associated with debt.
• Employees: The funding supports ongoing operations and job security.
• Customers: The funding supports continued product development and service delivery.
• Suppliers: The funding ensures timely payments and continued business relationships.
• Creditors: The new credit facility impacts the priority of claims in case of default.

Next Steps

• DarioHealth will use the proceeds from the credit facility to refinance existing debt and support its business operations.
• The company will need to meet certain revenue and gross margin thresholds to access the additional $2.5 million term loan.
• DarioHealth will need to comply with the covenants in the credit agreement to avoid triggering an event of default.

Key Dates

Keywords

Credit Agreement, Term Loan, DarioHealth, Warrants, Debt, Financing, Lenders